Cardiac Troponin Market Size
The Global Cardiac Troponin Market reached approximately US$ 5.18 billion in 2025 and is expected to reach US$ 12.09 billion by 2033, growing at a CAGR of 11.2% during the forecast period 2026–2033.
Cardiac troponin generally is a test that detects damage to the heart muscle. Troponin is a protein that occurs in the blood only when the heart muscle is damaged, as in a heart attack. Other reasons for elevated troponin exist, but a heart attack is the most familiar. The test does not measure the low amounts of troponin normally in blood. Troponin T is highly sensitive (hs-TnT) and has been used for advanced tests.
Cardiac Troponin Market Scope
| Metrics | Details |
| Market CAGR | 11.2% |
| Segments Covered | By Type, By Location of Testing, By Application, By End User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Cardiac Troponin Market Dynamics
The global cardiac troponin market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of cardiovascular patients, improving patient awareness, and rising patient healthcare expenditure.
An increasing prevalence of cardiovascular disease drives the market growth
The rising awareness of the cardiovascular disease and healthcare infrastructure drive the global market. As per the World Health Organization (WHO), cardiovascular disease is the leading cause of death worldwide. Each year around 17.9 million people suffer from cardiovascular disease. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths happen prematurely in people under 70. Rising patients with the disease need to diagnose the disease drives the market.
Cardiac troponin is an identified biomarker that can impact a change in the care of a patient with acute coronary syndrome. Troponin protein is released from damaged heart muscle into the bloodstream. New high-sensitivity blood tests allow the detection of a very low troponin level soon after the onset of symptoms. The electrocardiogram (ECG) measures the heart’s electrical activity and can show abnormalities in a heart attack.
Cardiac Troponin Market Segmentation Analysis
The point-of-care testing segment is expected to grow at the fastest CAGR during the forecast period (2026-2033)
By Type:
- Troponin I
- Troponin T
- Others
By Location of Testing:
- Laboratory Testing
- Point of Care Testing
The point of care testing segment accounts for the largest market share. The rising adoption of point-of-care testing systems for health records is expected to boost the market over the forecast period. This promotes accessibility of POCT results, the ability to monitor and trend, prevents unnecessary repeat testing and provides evidence for patient outcomes.
As POCT results are used to make clinical decisions, it is important to document results with associated reference intervals, units of measurement, critical values if applicable, date and time of testing, and also be traceable to device serial number, operator identification number, reagent lot number, and quality control (QC) results. POCT results should also be clearly differentiated from other central laboratory results to avoid confusion and trending results from different analytical methodologies. POCT is currently routine in all hospitals and has become the standard for patient care in a variety of other healthcare settings. Cardiac troponin is accurately performed by POCT.
By Application:
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
By End User:
- Hospitals
- Diagnostic Centers
Cardiac Troponin Market Geographical Share
North America region holds the largest market share of the global cardiac troponin market
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East and Africa
North America dominates the market for cardiac troponin and is expected to show a similar trend over the forecast period. The market is driven by the factors such as increasing demand for diagnosis of cardiac disease and advancements in cardiac biomarkers.
In addition, the market players are offers the products in the United States region. For instance, Quidel Corporation provides TriageTrueTM High Sensitivity Troponin I Test for the quantitative determination of troponin I in EDTA anticoagulated whole blood and plasma specimens. The test is to be indicated as an aid in the diagnosis of myocardial infarction (MI) for use with Quidel’s Triage MeterPro instrumented system.
Cardiac Troponin Market Companies and Competitive Landscape
The cardiac troponin market is a moderately competitive presence of local and global companies. Some of the key players contributing to the market's growth are Biomerieux, Beckman Coulter, Siemens Healthcare, Roche, Fujirebio, Abbott, LifeSign, Alere, and Singulex, among others. The major players are adopting several growth strategies, such as product launches, acquisitions, and collaborations, contributing to the growth of the cardiac troponin market globally.
For instance,
Biomerieux
Overview:
Biomerieux is a French multinational biotechnology organization founded in 1963 and headquartered in France. It offers innovative products and services to meet the need for global solutions.
Recent Development-
- September 30, 2025: F. Hoffmann-La Roche Ltd. announced positive results and CE Mark approval for its Elecsys® Troponin T high-sensitivity Gen 6 assay, validated through the global TSIX study involving 13,000+ patients, enabling faster and more precise heart attack diagnosis in emergency settings.
- October 2025: Abbott Laboratories continued expansion of its high-sensitivity cardiac troponin I (hs-cTnI) testing platforms, strengthening integration with Alinity diagnostic systems across U.S. hospitals to support rapid rule-out protocols (0–1 hour algorithms) for myocardial infarction diagnosis (validated via ongoing clinical adoption trends and company diagnostics portfolio updates).
- November 2025: Siemens Healthineers AG advanced adoption of its high-sensitivity troponin I assays across U.S. clinical laboratories, focusing on predictive analytics for early cardiac event detection and workflow integration with digital decision-support systems.
- September 30, 2025: F. Hoffmann-La Roche Ltd. included Japan and broader Asia-Pacific populations in its TSIX global clinical program, ensuring standardized troponin thresholds and improving diagnostic consistency across regional healthcare systems.
- August–October 2025: Sysmex Corporation expanded its cardiac biomarker testing portfolio, including troponin assays, across Asia-Pacific markets with a focus on automated laboratory systems and hospital integration for cardiovascular disease diagnostics (based on company portfolio expansion trends and regional deployment activities).
The global Cardiac Troponin market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
